Vertical: HealthcareBase Year: 202434 Sections
Market Size (2024)
$3.95B
Projected (2035)
$12.41B
CAGR (2019–2035)
10.1%
Key Players
8+
This report covers Immuno-oncology Assay Market with forecasts from 2019 to 2035. 8 key companies are profiled.
The Immuno-oncology Assay Market market is projected to grow at a CAGR of 10.1% from 2019 to 2035.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The rising incidence of cancer, along with government and private funding for cancer research, are key factors contributing to the growth of the global immuno-oncology assay market. However, the high cost of immuno-oncology assays and the lack of a skilled workforce are expected to hamper market expansion. Nevertheless, the growing geriatric population and technological advancements are anticipated to create lucrative opportunities for industry.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2024
Historical Period
2019 – 2023
Forecast Period
2025 – 2035
Primary Interviews
150+
Historical data (2019–2024) and forecast period (2024–2035)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMichael Porter's Five Forces model is a framework to study the global immuno-oncology assay market. Strategic business managers trying to gain an edge over competing firms in the global immuno-oncology assay market can utilize this model to better comprehend the industry in which the firm operates. The components of each of the forces and the degree of impact of each component in the context of the global immuno-oncology assay market have been broken down and analyzed.
PORTER'S FIVE FORCES Analysis: Global Immuno-Oncology Assay Market
Threat of New Entrants
The threat of new entrants in the global immuno-oncology assay market is moderate to high, primarily due to the growing demand for precision oncology and advancements in biomarker technologies. While regulatory approvals, high R&D costs, and the need for technical expertise present barriers to entry, these are increasingly being overcome by startups and biotech firms entering the space with novel, targeted solutions. The fragmented nature of the market lowers entry barriers further, as new players can target niche segments or focus on specific technologies without directly competing with the larger incumbents. Additionally, ongoing innovation in immune profiling, multiplex assays, and liquid biopsy technologies continue to create openings for differentiated offerings, making it easier for new entrants to gain a foothold.
BARGAINING POWER OF SUPPLIERS
The bargaining power of suppliers in this market is low to moderate, influenced by the availability of multiple suppliers of key assay components such as reagents, antibodies, and consumables. Given the market fragmentation, suppliers are often competing to serve a broad base of diagnostic companies and laboratories, which limits their ability to dictate prices. However, in cases where companies are dependent on proprietary reagents or highly specialized biological materials, supplier power can increase slightly due to switching costs or limited availability. Nonetheless, most assay developers maintain relationships with multiple vendors, and global supply chain diversity helps keep supplier influence in check.
Threat of Substitutes
The threat of substitutes is moderate, with emerging diagnostic technologies such as liquid biopsies, next-generation sequencing (NGS), and advanced imaging techniques potentially replacing or complementing immuno-oncology assays. These alternatives may offer different types of clinical information or be more cost-effective in some scenarios. However, immuno-oncology assays provide unique value by offering biomarker-specific insights that guide immunotherapy decisions, making them difficult to fully replace. Moreover, their growing integration into clinical decision-making and pharmaceutical development pipelines strengthens their position, although continual technological evolution means the risk of substitution remains relevant in the long term.
Bargaining Power of Buyers
The bargaining power of buyers in the global immuno-oncology assay market is moderate to high, largely due to the fragmented supplier landscape and the presence of numerous options in terms of assay platforms, service providers, and diagnostic tools. Buyers, including hospitals, research institutions, pharmaceutical companies, and diagnostic labs, often have the leverage to negotiate pricing, demand customization, and expect performance validation, especially when purchasing in high volumes. The increasing cost pressures in healthcare systems and the push for value-based care also encourage buyers to seek cost-effective solutions, further increasing their influence over assay providers. This dynamic incentivizes assay developers to differentiate through innovation, partnerships, and value-added services.
Intensity of Rivalry
The intensity of competitive rivalry in the immuno-oncology assay market is high, fueled by the large number of players—ranging from global diagnostic companies to specialized biotech firms—vying for market share. Product differentiation is often based on assay sensitivity, turnaround time, biomarker range, regulatory approvals, and clinical utility. However, in such a fragmented market, many companies target overlapping applications, leading to price competition and frequent innovation cycles. As firms seek to establish long-term collaborations with pharmaceutical companies and healthcare institutions, the race to develop the most predictive and cost-effective assays intensifies. This environment of rapid technological advancement and pricing pressure sustains a high level of rivalry among both established and emerging market participants.
Impact of covid-19 on the Global Immuno-Oncology Assay Market
The COVID-19 pandemic exerted a moderately negative impact on the global immuno-oncology assay market. While the crisis led to short-term disruptions in clinical operations, diagnostics, and supply chains, the essential nature of oncology care and the long-term growth potential of immuno-oncology testing helped the market stabilize and recover more quickly than some other healthcare segments. The pandemic functioned as both a stress test and a transformation trigger for the sector, exposing vulnerabilities but also accelerating key trends in digital health and personalized medicine.
During the initial stages of the pandemic in 2020, healthcare systems globally shifted their focus almost entirely to managing the surge in COVID-19 cases. As a result, non-urgent procedures and routine cancer screenings were delayed or suspended, leading to a measurable decline in the volume of diagnostic testing, including immuno-oncology assays such as PD-L1, TMB (tumor mutational burden), and microsatellite instability (MSI) testing. Hospitals postponed elective procedures, and patients avoided clinical visits out of fear of contracting the virus, reducing the demand for both standalone and companion diagnostic assays.
Additionally, clinical trials in oncology faced disruptions, with many trials paused or slowed due to resource reallocation, recruitment challenges, and restricted patient mobility. Since immuno-oncology assays are integral to biomarker discovery and patient stratification in cancer trials, these disruptions led to a moderate decline in assay utilization and sales across the industry. However, unlike elective care, oncology treatment and research could not be paused indefinitely, so these declines were temporary, with many institutions resuming trials and diagnostics by mid to late 2021.
Global supply chains were severely affected by the pandemic, and the immuno-oncology assay market was not immune. Delays in the supply of critical raw materials, such as reagents, antibodies, and specialized assay kits, created bottlenecks for assay developers and diagnostic laboratories. Companies reliant on just-in-time inventory systems or international suppliers experienced significant procurement challenges, especially during lockdowns and transportation restrictions.
Furthermore, operational inefficiencies arose as laboratories and production facilities had to implement safety measures, limit staff presence, or temporarily shut down. Smaller assay developers, particularly those in early stages of commercialization, faced greater exposure to these disruptions, which limited their ability to meet ongoing or future diagnostic demands. While these issues did not result in a systemic collapse, they contributed to project delays and temporary revenue losses, constituting a moderate headwind for the market during the peak of the pandemic.
Another negative consequence of the pandemic was the short-term reallocation of research funding from oncology toward infectious disease efforts. Government grants, private investments, and institutional budgets were redirected to support the development of COVID-19 diagnostics, treatments, and vaccines.
Market estimates by geography (2035)
InsightNorth America leads with $4.70B by 2035, while Asia-Pacific is projected to grow fastest at a 12.4% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2019 | 2024 | 2035 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $1.17B | $2.22B | $4.70B | 9.1% | 38% |
| Europe | $780.98M | $1.62B | $3.74B | 10.3% | 30% |
| Asia-Pacific | $480.01M | $1.17B | $3.12B | 12.4% | 25% |
| South America | $134.21M | $235.40M | $452.83M | 7.9% | 4% |
| Middle East and Africa | $101.93M | $195.17M | $392.04M | 8.8% | 3% |
| Total | $2.67B | $5.44B | $12.41B | 10.1% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$12.41B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Reagents & Kits | $8.12B | 9.5% | 33% |
| Instruments | $4.29B | 11.3% | 17% |
| Immune Cell Profiling Assays | $3.82B | 11.1% | 15% |
| Cytokine Release Assays | $2.40B | 8.8% | 10% |
| Tumor Mutation Burden Assays | $2.34B | 13.8% | 9% |
| Cytotoxicity Assays | $2.01B | 9.5% | 8% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Immuno-oncology Assay Market covering market dynamics, competitive landscape, and strategic outlook.
The Immuno-oncology Assay Market market is projected to reach $12.41B by 2035, growing at 10.1% CAGR. The Reagents & Kits segment holds the largest share.
Introduction
The rising incidence of cancer, along with government and private funding for cancer research, are key factors contributing to the growth of the global immuno-oncology assay market. However, the high cost of immuno-oncology assays and the lack of a skilled workforce are expected to hamper market expansion. Nevertheless, the growing geriatric population and technological advancements are anticipated to create lucrative opportunities for industry.
Rising Incidence of Cancer
The rising global incidence of cancer has become a critical public health challenge, driven by a convergence of factors including increased life expectancy, urbanization, dietary changes, tobacco use, environmental pollution, and sedentary lifestyles. As cancer cases continue to rise, the complexity and heterogeneity of tumors necessitate advanced diagnostic tools that extend beyond conventional methods.
According to the Global Cancer Observatory, the estimated number of new cancer cases between 2022 and 2025, across both sexes and all cancer types, is as follows: Asia – 9,826,539; Europe – 4,471,422; Northern America – 2,850,879; Latin America and the Caribbean – 1,629,786; Africa – 1,301,241; and Oceania – 293,175.
In this context, immuno-oncology has emerged as a transformative approach, leveraging the body’s immune system to detect and eliminate cancer cells. Immuno-oncology assays play a pivotal role in this paradigm shift, offering precise and dynamic tools to analyze tumor-immune interactions, monitor immune responses, and identify both predictive and prognostic biomarkers. These assays empower clinicians and researchers to determine which patients are most likely to respond to specific immunotherapies, thereby improving treatment efficacy and reducing adverse effects.
The growing focus on precision medicine—coupled with the increasing adoption of combination immunotherapies and adaptive clinical trial designs—is accelerating the integration of immuno-oncology assays in both clinical practice and research. This momentum is driving the expansion of the global immuno-oncology assay market, as stakeholders across the pharmaceutical, biotechnology, and diagnostics industries invest in innovative assay technologies to meet the rising demand for personalized, immune-based cancer care.
Government and Private Funding for Cancer Research
Robust government and private sector funding for cancer research is significantly accelerating the growth of the global immuno-oncology (I-O) assay market. Large-scale investments by national health agencies and private foundations are fueling innovation in cancer diagnostics and personalized therapies. These funds support biomarker discovery, clinical trials, and the development of cutting-edge diagnostic platforms—including I-O assays—that enable precise patient stratification and therapy monitoring. For example, the Government of India has taken significant steps toward combating cancer and enhancing public health, allocating $1.20 billion (₹99,858.56 crore) to the Ministry of Health and Family Welfare in the recent budget. Of this, $1.15 billion (₹95,957.87 crore) is earmarked for the Department of Health and Family Welfare, and $47 million (₹3,900.69 crore) for the Department of Health Research. Among the notable initiatives is the plan to establish 200 Day Care Cancer Centres in district hospitals by 2025–26, significantly improving access to oncology services in underserved regions. To further support cancer care and the treatment of rare and chronic diseases, the government has introduced customs duty exemptions. A total of 36 life-saving drugs have been exempted from Basic Customs Duty (BCD), while six essential medicines now benefit from a concessional duty rate of 5%.
In the private sector, organizations such as the Breast Cancer Research Foundation (BCRF) are also making substantial contributions. In September 2024, BCRF announced an investment of $70.3 million—its largest annual funding program in the organization’s 31-year history—to support breast cancer research for the 2024–2025 cycle. This investment will fund more than 260 scientists at leading academic and medical institutions across 16 countries. The funding spans the entire spectrum of the disease, from its earliest origins to its most advanced stage: metastatic breast cancer.
Together, these government initiatives and private investments are strengthening the research ecosystem, fostering collaboration, and driving demand for innovative immuno-oncology assays. This financial momentum is critical in expanding the global market, enhancing the precision and effectiveness of immune-based cancer treatments worldwide.
The expanding global geriatric population is emerging as a key driver of growth for the immuno-oncology (I-O) assay market. Older adults are at significantly higher risk of developing cancer due to age-related genetic mutations, immune system decline, and cumulative exposure to environmental risk factors. As a result, the demand for personalized, immune-based diagnostic solutions is rising in this demographic segment. Immuno-oncology assays, which help identify predictive biomarkers and assess immune response, are becoming essential tools in tailoring treatment strategies for elderly cancer patients—who often face unique clinical challenges due to comorbidities and reduced treatment tolerance. For instance, according to the World Data Atlas, the population aged 65 years and above in Argentina increased by 1.40%, rising from 12.1% in 2023 to 12.2% in 2024. Since a 1.10% growth in 2014, the population aged 65 and above has grown by 11.22% as of 2024. Moreover, according to Eurostat, the number of centenarians in the EU-27 is projected to reach nearly half a million by 2050. Women significantly outnumber men at older ages within the EU-27; in 2019, there were more than twice as many women aged 85 and over compared to men in the same age group.
The median age is expected to rise by 4.5 years—from 43.7 in 2019 to 48.2 by 2050, reflecting the broader aging trend. While the total population of the EU-27 is projected to grow slightly from 446.8 million in early 2019 to a peak of 449.3 million between 2026 and 2029, it is expected to gradually decline to 441.9 million by 2050. These demographic shifts underscore the growing need for advanced cancer diagnostics capable of guiding immunotherapy decisions in aging populations, thereby creating substantial growth opportunities for the global immuno-oncology assay market. Rapid technological advancements in immunohistochemistry (IHC) and biomarker development are creating lucrative growth opportunities in the global immuno-oncology assay market. For instance, in February 2020, Biocare edical’s launched seven novel IVD IHC antibody markers for clinical diagnostics and research applications. This product expansion includes several cutting-edge immuno-oncology markers that are instrumental in accelerating early-stage cancer drug development and improving patient stratification for targeted therapies. Among these innovations is the redevelopment of the S100 protein antibody, which is widely used in the detection of Schwannomas, ependymomas, astrogliomas, and nearly all benign and malignant melanomas.
Biocare’s enhanced version, S100, offers a significantly stronger and more robust staining signal, improving the sensitivity and accuracy of IHC applications. Such technological breakthroughs not only enhance diagnostic precision but also support the growing demand for personalized oncology solutions driving market expansion and attracting investment across diagnostics, biotech, and pharmaceutical sectors.
High Cost of Immuno-Oncology Assays
The high cost of immuno-oncology (I-O) assays presents a significant restraint on the growth of the global immuno-oncology assay market. These assays often require advanced technologies, specialized reagents, and highly skilled personnel, all of which contribute to substantial development and operational expenses. Additionally, the complexity of immuno-oncology testing, which frequently involves multiplex biomarker analysis and integration with sophisticated platforms such as next-generation sequencing (NGS) or flow cytometry, further drives up costs. This financial burden limits the accessibility and adoption of these assays, particularly in low- and middle-income countries where healthcare budgets are constrained. Furthermore, reimbursement challenges and inconsistent insurance coverage for these advanced diagnostic tests create additional barriers for widespread clinical implementation. As a result, despite the growing demand for personalized immunotherapy approaches, the elevated cost of I-O assays slows market penetration and restricts broader utilization in routine clinical practice, ultimately hindering the expansion of the global immuno-oncology assay market.
Lack of Skilled Workforce
The limited understanding of immuno-oncology (I-O) assay technologies among healthcare professionals and diagnostic stakeholders remains a critical barrier to the expansion of the global immuno-oncology assay market. These assays rely on advanced platforms such as next-generation sequencing (NGS), multiplex immunohistochemistry, and flow cytometry, which require specialized technical knowledge for accurate execution and interpretation. In many clinical settings—particularly in emerging markets—there is a shortage of trained personnel and infrastructure to support the integration of these complex diagnostic tools into standard care workflows. Moreover, the rapid evolution of assay technologies often leads to a disconnect between innovation and end-user readiness, resulting in underutilization of available solutions. This knowledge gap affects both clinical decision-making and institutional investment in I-O diagnostics, as stakeholders may be hesitant to adopt technologies they do not fully understand or cannot effectively operationalize. As a result, despite strong demand for precision oncology solutions, the lack of awareness and technical competency continues to restrain the broader adoption and scalability of immuno-oncology assays in global healthcare markets.
The expanding global geriatric population is emerging as a key driver of growth for the immuno-oncology (I-O) assay market. Older adults are at significantly higher risk of developing cancer due to age-related genetic mutations, immune system decline, and cumulative exposure to environmental risk factors. As a result, the demand for personalized, immune-based diagnostic solutions is rising in this demographic segment. Immuno-oncology assays, which help identify predictive biomarkers and assess immune response, are becoming essential tools in tailoring treatment strategies for elderly cancer patients—who often face unique clinical challenges due to comorbidities and reduced treatment tolerance. For instance, according to the World Data Atlas, the population aged 65 years and above in Argentina increased by 1.40%, rising from 12.1% in 2023 to 12.2% in 2024. Since a 1.10% growth in 2014, the population aged 65 and above has grown by 11.22% as of 2024. Moreover, according to Eurostat, the number of centenarians in the EU-27 is projected to reach nearly half a million by 2050. Women significantly outnumber men at older ages within the EU-27; in 2019, there were more than twice as many women aged 85 and over compared to men in the same age group.
The median age is expected to rise by 4.5 years—from 43.7 in 2019 to 48.2 by 2050, reflecting the broader aging trend. While the total population of the EU-27 is projected to grow slightly from 446.8 million in early 2019 to a peak of 449.3 million between 2026 and 2029, it is expected to gradually decline to 441.9 million by 2050. These demographic shifts underscore the growing need for advanced cancer diagnostics capable of guiding immunotherapy decisions in aging populations, thereby creating substantial growth opportunities for the global immuno-oncology assay market.
Technological Advancements
Rapid technological advancements in immunohistochemistry (IHC) and biomarker development are creating lucrative growth opportunities in the global immuno-oncology assay market. For instance, in February 2020, Biocare Medical’s launched seven novel IVD IHC antibody markers for clinical diagnostics and research applications. This product expansion includes several cutting-edge immuno-oncology markers that are instrumental in accelerating early-stage cancer drug development and improving patient stratification for targeted therapies. Among these innovations is the redevelopment of the S100 protein antibody, which is widely used in the detection of Schwannomas, ependymomas, astrogliomas, and nearly all benign and malignant melanomas. Biocare’s enhanced version, S100, offers a significantly stronger and more robust staining signal, improving the sensitivity and accuracy of IHC applications. Such technological breakthroughs not only enhance diagnostic precision but also support the growing demand for personalized oncology solutions driving market expansion and attracting investment across diagnostics, biotech, and pharmaceutical sectors.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 103 companies operating in the Immuno-oncology Assay Market market, including revenue, employee count, and market positioning where available.
Showing 103 of 103 companies
Company Headquarters: Germany, Europe Founded: 1984 Workforce: 5,000 Company Working: Qiagen is a healthcare company that deals in sample and assay technologies for molecular diagnostics. The company operates through more than 35 offices spread in over 25 countries. It serves more than 500,000 customers across the globe. Its product portfolio spans through a full range of molecular testing applications. Qiagen’s products are used for extraction, purification, and stabilization of DNA, RNA, and protein from various biological samples. It has over 500 core products in its portfolio. The company is listed on the New York Stock and Frankfurt Prime Standard exchanges. It offers its products in various areas such as discovery & translational research, diagnostics & clinical research, next-generation sequencing, and instruments & automation.
Merck KGaA is a 358-year-old, family-controlled, diversified science and technology group generating EUR 21.1 billion of net sales (FY2025) across three complementary business sectors: Life Science (42% of sales; a top-three global supplier of research tools, bioprocessing consumables and testing services, known in North America as MilliporeSigma), Healthcare (41%; a specialty pharmaceutical company with established franchises in oncology, multiple sclerosis, fertility and cardiometabolic care plus a new rare-tumour franchise acquired via SpringWorks), and Electronics (17%; a now pure-play semiconductor and optronics materials, equipment and metrology supplier exposed to AI-driven advanced nodes). The group operates at a ~29% EBITDA pre margin with net financial debt of ~1.4x EBITDA pre. Its investment case rests on three growth drivers — Process Solutions, Rare Diseases and Semiconductor Solutions — which management expects to generate up to 80% of medium-term growth, now being reinforced by the pending US$11.3 billion Bio-Techne acquisition. --- ### Company's own description (paraphrased from AR 2025) The company describes itself as a science and technology company guided by the vision "Sparking Discovery, Elevating Humanity," working across Life Science, Healthcare and Electronics to create value for customers and patients. The founding family, now in its 13th generation, remains majority owner through the KGaA structure. Financial reporting presents three business sectors plus Corporate and Other, and five regions (Europe, North America, Asia-Pacific, Latin America, Middle East and Africa). The company's own boilerplate (2026 press releases) characterises its activity as accelerating drug development and manufacturing, discovering treatments for challenging diseases, and enabling "the intelligence of devices." ### Independent characterisation Merck KGaA is best understood as a conglomerate of three high-margin specialty businesses with distinct economic cycles: 1. **Life Science** is a consumables-heavy, recurring-revenue tools franchise. Roughly 42% of sector sales (Process Solutions) are "embedded" in customers' validated biomanufacturing processes (filters, chromatography resins, single-use assemblies, cell culture media, excipients), creating high switching costs because regulatory re-validation is required to change suppliers. The research catalogue business (legacy Sigma-Aldrich; now Discovery Solutions) is a broad, transactional, e-commerce-led reagent business with more than 300,000 products. Services (testing, CDMO for ADCs/viral vectors/HPAPIs) are smaller and lumpier. 2. **Healthcare** is a mid-sized specialty pharma business whose cash generation rests disproportionately on mature, off-patent or near-off-patent brands (Glucophage, Concor, Euthyrox, Erbitux, Rebif, Gonal-f) and on Mavenclad, which began losing US exclusivity in 2026. The SpringWorks acquisition (July 2025) created a Rare Diseases franchise (Ogsiveo, Gomekli/Ezmekly, pimicotinib) intended to offset these erosions. Historically, internal R&D productivity has been weak (late-stage failures of evobrutinib and xevinapant in 2023–2024). 3. **Electronics** is a materials-and-process-solutions supplier to semiconductor fabs (logic, memory, advanced packaging) and display panel makers. Following the Versum Materials (2019) and AZ Electronic Materials (2014) acquisitions and the 2025 divestment of Surface Solutions (pigments), it is positioned as a pure-play electronics business with 72% of sector sales in Asia-Pacific. ### Revenue model mix The company does not disclose a product/service/subscription/licensing percentage split. Analyst view: product sales (consumables, materials and medicines) constitute the overwhelming majority (>90%) of group revenue; this is an estimate and is flagged as such. ### Value-chain position and customers Regional mix of sector sales (AR 2025): Life Science 71% Europe + North America, 28% Asia-Pacific + Latin America; Healthcare 54% Europe + North America, 39% Asia-Pacific + Latin America; Electronics 72% Asia-Pacific, 26% Europe + North America.
Codexis is a Redwood City-based enzyme engineering company in the middle of a deliberate transition. It is moving from a diversified "protein engineering" platform company, whose revenue was historically dominated by custom biocatalysts for small-molecule drug manufacturing, toward a focused provider of enzymatic manufacturing solutions for oligonucleotide therapeutics, chiefly siRNA/RNAi. Its proprietary CodeEvolver® directed-evolution platform underpins two businesses. The first is a cash-generating but lumpy pharma biocatalysis franchise, anchored by long-standing relationships with Merck & Co. and other large pharmaceutical companies, which supports about 14 commercial products. The second is the pre-commercial ECO Synthesis® Manufacturing Platform, which aims to replace solid-phase phosphoramidite chemistry with enzymatic routes, together with a commercially launched dsRNA ligase. The company is a sub-$200 million market capitalization micro-cap and remains loss-making. It has about $80 million of pro forma liquidity, a $40 million term loan, and guidance for FY2026 revenue of $72–76 million. --- ### Company's own description (FY2025 10-K / standard press-release boilerplate, paraphrased) Codexis describes itself as a leading provider of enzymatic solutions for efficient, scalable therapeutics manufacturing. It discovers, develops and improves high-performance enzymes using its proprietary CodeEvolver® technology. According to the company, its enzymes address real-world problems in small-molecule pharmaceutical manufacturing and nucleic acid synthesis. Codexis is developing the ECO Synthesis® Manufacturing Platform to enable scaled manufacture of RNAi therapeutics through an enzymatic route. It says its enzymes can raise yields, cut energy use and waste, improve manufacturing efficiency, and increase sensitivity in genomic and diagnostic applications (Codexis Q4 FY2025 and Q2 FY2026 press releases). The FY2025 10-K states that headquarters is both the administrative centre and the centre of research, development and business operations, with limited internal manufacturing capacity. In-house manufacturing produces Codex® biocatalyst panels and kits, plus enzymes for customers' pilot-scale and clinical production. The ECO Synthesis Innovation Lab sits inside headquarters and is designed to supply non-GMP material in quantities that support customers' preclinical development. The company expects to partner with CDMOs for bulk GMP-grade siRNA production for clinical supply and beyond. ### Independent characterization Codexis is best understood as a technology-licensing and specialty-enzyme supplier whose economics depend on a small number of very large pharmaceutical relationships. In FY2025 a single customer accounted for about 51% of total revenue (FY2025 10-K, "Customers"). Given the $37.8 million Merck agreement recognised mainly in Q4 FY2025, that customer is almost certainly Merck. The business model has three monetization layers. The first layer is product revenue: sales of engineered enzymes (biocatalysts), pharmaceutical intermediates, Codex® biocatalyst screening panels and kits, and, increasingly, ligase and ECO enzyme supply. Product revenue is driven by customers' commercial manufacturing schedules and is therefore volatile quarter to quarter. Product gross margin has improved structurally, from 56% in FY2024 to 64% in FY2025 and 71–73% in Q1–Q2 FY2026. Management attributes this to a shift toward higher-margin products and the run-off of lower-margin legacy products. The second layer is research and development revenue: CodeEvolver platform licence fees, technology-transfer payments, milestone payments, feasibility and evaluation fees, and ECO Synthesis manufacturing services (for example, the low-seven-figure contract to supply 50 g of siRNA). In FY2025 R&D revenue exceeded product revenue for the first time in the period analysed ($44.4 million vs. $26.0 million). The main reason was the Merck technology transfer. The third layer is royalty and contingent consideration from out-licensed or divested assets. These include the Nestlé Health Science CDX-7108 sale (up to $45 million in milestones plus a single-digit royalty), the Aldevron HiCap RNA polymerase licence (milestones and royalties), and the Roche dsDNA ligase licence (upfront and technical milestones). These are largely back-ended and uncertain. **Value-chain position.** Codexis sits upstream of drug-substance manufacturing. It supplies process technology (enzymes and the know-how to use them) to innovator pharma companies, generic manufacturers and CDMOs, which then run the commercial processes. In the oligonucleotide chain it is trying to move one step downstream. Its planned ECO GMP Manufacturing Center would make siRNA material for preclinical and Phase 1 supply. This hybrid "tool supplier plus early-phase manufacturer" model is a new risk profile for the company. **Customer types:** large innovator pharma (Merck, plus historically Pfizer, GSK and Novartis); high-growth RNAi biotech innovators (unnamed counterparties in 2025–2026 agreements); CDMOs (Bachem, Nitto Denko Avecia, Axolabs); and life-science tools companies (Roche, Aldevron, seqWell). **End-markets served:** small-molecule API manufacturing (biocatalysis); oligonucleotide/RNAi therapeutic manufacturing; and, as a residual licensing stream, life-science tools and genomics reagents. ### Revenue model mix (FY2021–FY2025) *Sources: Q4 FY2022 press release (FY2021–FY2022 PAXLOVID figures); FY2023 10-K (product revenue); Q4 FY2023 press release (ex-PAXLOVID revenue of $62.0 million implies about $8.1 million PAXLOVID-related revenue in FY2023, largely the release of deferred Pfizer fees); Q4 FY2025 8-K Exhibit 99.1 (FY2024–FY2025). Shares are computed.*
Sanofi is a top-tier global biopharmaceutical company that has, over six years, deliberately narrowed itself from a diversified healthcare conglomerate into a single-segment, R&D-led specialty medicines and vaccines business. Its centre of gravity is immunology: Dupixent, co-developed with Regeneron, generated €15.7bn in FY2025 — 36% of group sales — and management now guides to approximately €25bn by 2030. Around that core sit a differentiated rare-disease franchise (Pompe, Gaucher, Fabry, haemophilia, ASMD), the world's broadest vaccines portfolio outside Merck and GSK, and a smaller oncology and neurology presence. The company shed EUROAPI in 2022 and sold control of Opella consumer health to CD&R in 2025 for €10.4bn net. Financially it is unusually clean — 77.5% business gross margin, 0.8x net debt/EBITDA, 31 consecutive years of dividend increases. The unresolved question, and the reason for a February 2026 CEO change, is whether its internal pipeline can replace Dupixent's eventual erosion. *Caveat: Sanofi does not publish a single headline headcount in its quarterly releases. The FY2021 figure derives from the company's 2022 employee share plan disclosure ("over 90,000 employees in 73 countries" eligible in 2021); the FY2024/FY2025 figure of ~83,000 is the company-sourced number cited in industry reporting at the time of the March 2025 US investment announcement, reflecting both restructuring and the Opella separation. Precise year-end FTE counts are disclosed in the Universal Registration Document / Form 20-F and are not restated here. The 2025 employee share plan was offered to "around 70,000 employees in 55 countries" — an eligibility population, not total headcount.* --- ### What Sanofi does Sanofi researches, develops, manufactures and commercialises prescription medicines and human vaccines. Since January 1, 2025 it reports one operating segment, Biopharma, plus an immaterial "Other" line that captures residual Opella-related transitional revenues and manufacturing services. Sanofi's own characterisation, used verbatim in every 2026 press release, is: *"Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world."* The formal segment description in its 2025 shelf-registration prospectus reads: *"We have one operating segment: Biopharma. It comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises plus support and corporate functions, for all geographical territories."* Internally, and in the reporting taxonomy adopted from FY2025, the business is organised as: - **Pharma** - *Immunology* — Dupixent, Kevzara - *Rare diseases* — Fabrazyme, Cerezyme/Cerdelga, Myozyme/Nexviazyme, Aldurazyme, Xenpozyme, ALTUVIIIO, Eloctate, Alprolix, Cablivi, Qfitlia, Wayrilz, Ayvakit - *Neurology* — Aubagio (in run-off), Cenrifki (tolebrutinib) - *Oncology* — Sarclisa, Jevtana, Fasturtec - *Other main / established medicines* — Lantus, Toujeo, Apidra, Soliqua, Plavix, Lovenox, Aprovel, Multaq, Praluent, Thymoglobulin, Rezurock, Synvisc - **Vaccines** — influenza (Fluzone/Efluelda/Vaxigrip), polio/pertussis/Hib (Pentacel, Pentaxim, Hexaxim, Vaxelis via JV), meningitis (Menactra, MenQuadfi), travel/endemic (rabies, yellow fever, typhoid, hepatitis A), Beyfortus (RSV mAb, with AstraZeneca), Nuvaxovid (COVID-19), Heplisav-B (adult hepatitis B, acquired with Dynavax) ### Revenue model Sanofi's revenue is overwhelmingly product sales of patented and off-patent pharmaceuticals and vaccines — there is effectively no subscription or service revenue. The economics have four distinct layers: 1. **Net sales (€43,626m FY2025)** — gross invoiced product sales less gross-to-net deductions (US rebates, Medicaid/340B, chargebacks, ex-US statutory price cuts, China VBP/NRDL). 2. **Other revenues (€3,090m FY2025)** — a materially different-margin stream comprising VaxServe's distribution of *non-Sanofi* vaccines in the US (€1,780m FY2025, declining), manufacturing services (€557m), transitional sales of Opella products in certain markets (€487m), and royalties (€146m). 3. **Alliance profit-sharing, recorded in other operating income/expenses** — this is the single most important non-obvious feature of Sanofi's P&L. Sanofi books 100% of worldwide Dupixent and Kevzara sales but must then pay Regeneron its share of alliance profit. In FY2025 the total charge related to Regeneron was €4,923m, of which €5,065m was the monoclonal-antibody alliance net (profit/loss share −€5,455m, plus €1,089m of Regeneron's contribution to development costs, less €699m reimbursement of Regeneron commercial operating expenses). This charge grew 28% year-on-year and structurally caps Sanofi's operating leverage on its fastest-growing asset. 4. **Out-licensing royalties** — notably the Amvuttra royalty (€398m in H1 2026, up from €120m in H1 2025) and other license-out income (€495m FY2025). ### Value chain position and customers Sanofi is a fully integrated originator: discovery research, clinical development, regulatory, primary and secondary manufacturing (biologics, sterile injectables, vaccine bulk and fill-finish), and direct commercialisation in most markets. It also operates VaxServe, a US vaccine and specialty-pharmaceutical distribution business that carries third-party product — a rare downstream extension. Customers are institutional rather than retail: US wholesalers (McKesson, Cencora, Cardinal) and PBMs, national and regional health systems and tender authorities in Europe, public immunisation programmes and supranational buyers (UNICEF, PAHO, Gavi) for vaccines, hospital groups, and specialty pharmacies for rare disease and biologic products. End-markets are immunology and inflammation, rare genetic disease, haematology, multiple sclerosis, multiple myeloma, diabetes, cardiovascular disease, and paediatric and adult immunisation. ### Independent characterisation Functionally Sanofi is now one very large product (Dupixent) plus a durable but low-growth annuity book plus an option on a rebuilt pipeline. Dupixent contributed 36% of FY2025 net sales and 44.4% of Q2 2026 net sales, and grew 37.6% in Q2 2026 — meaning group growth is almost entirely one franchise. The vaccines business, historically Sanofi's defensive ballast, has become a source of volatility: it declined 1.2% in FY2025 and 1.1% in H1 2026, pressured by falling birth rates in China, US immunisation-policy uncertainty, and competitive tendering. The rare-disease and haemophilia portfolios are genuinely differentiated but individually sub-scale. The strategic problem management is now addressing is that Sanofi has bought growth (Blueprint, Dynavax, Vicebio) faster than it has generated it internally — and in July 2026 discontinued three of the assets that were supposed to be the answer.
Company Headquarters: Maryland, US Founded: 1987 Workforce: ~2,500 Company Working: Novavax, Inc. is a biotechnology company that commercializes and develops vaccines to prevent a wide range of infectious diseases. It designs recombinant nanoparticle vaccine technology that produces a strong immune response against a variety of pathogens. It is partnered with leading biopharma organizations, government agencies, research institutions, and foundations, namely the Coalition for Epidemic Preparedness Innovations (US), the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (US), the Serum Institute of India Pvt. Ltd. (India), SK Bioscience (South Korea), CPL Biological (India), and Takeda Pharmaceuticals (US). It has seven research and manufacturing facilities. It has presence in regions namely North America, Europe, and the Middle East and Africa
9 interactive charts drawn from the Immuno-oncology Assay Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Immuno-oncology Assay Market By Region
Global Immuno-oncology Assay Market By Indication
Global Immuno-oncology Assay Market By Assay Type
Global Immuno-oncology Assay Market By Country
Global Immuno-oncology Assay Market By End User
Global Immuno-oncology Assay Market By Application
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
